Image-guided EMT inhibition for treating metastatic breast cancer

图像引导 EMT 抑制治疗转移性乳腺癌

基本信息

  • 批准号:
    9301500
  • 负责人:
  • 金额:
    $ 47.39万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2015
  • 资助国家:
    美国
  • 起止时间:
    2015-07-01 至 2020-06-30
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): The goal of this project is to develop innovative image-guided EMT inhibition by targeting the proteins in the key biological event associated with metastasis using RNAi to effectively treat metastatic BC. Metastatic breast cancer is the leading cause of the premature deaths of women diagnosed with the disease in the United States. Currently, there are limited treatment options for the patients whose breast cancer becomes multidrug resistance and relapsed disease. Epithelial-mesenchymal transition (EMT) is a key biological event associated with breast cancer metastasis and multidrug resistance. We have identified several markers of breast cancer EMT for imaging metastatic breast cancer and for effective treatment of metastatic breast cancer by inhibiting cancer cell EMT and resensitizing the cells to chemotherapy under imaging guidance. In this project, we will develop molecular MRI and DCE-MRI to direct the inhibition of BC EMT using targeted lipid siRNA nanoparticles in treating metastatic BC. We will develop targeted multifunctional lipid siRNA delivery systems to down-regulate the expression of key proteins that promote cancer cell EMT for effective inhibition of BC EMT and treatment of metastatic BC alone and in combination with chemotherapy under imaging guidance. Non-invasive and timely assessment of therapeutic efficacy of the new therapeutic regimens using the imaging technologies will guide the optimization of the delivery systems and treatment protocols to achieve the best possible outcomes and to cure the disease. The specific aims of this project are 1) to first establish molecular imaging technologies for non-invasive image-guided inhibition of EMT with targeted multifunctional siRNA delivery systems in treating metastatic breast cancer; 2) to evaluate and optimize image-guided silence of EMT-regulatory genes and inhibition of BC EMT and metastasis using targeted multifunctional siRNA delivery systems; 3) to evaluate and optimize image-guided combination therapy of the multifunctional siRNA delivery systems and chemotherapeutics in treating TNBC. Substantial preliminary data have been obtained to demonstrate the effectiveness of the proposed image-guided therapeutic regimens in treating metastatic breast cancer. Our long-term goal is to develop an image-guided therapeutic approach to effectively treat life-threatening metastatic BC.
 描述(由申请人提供):该项目的目标是通过使用RNAi靶向与转移相关的关键生物事件中的蛋白质来开发创新的图像引导的EMT抑制,以有效治疗转移性BC。在美国,转移性乳腺癌是被诊断患有该疾病的妇女过早死亡的主要原因。目前,对于乳腺癌成为多药耐药和复发性疾病的患者,治疗选择有限。上皮-间质转化(EMT)是与乳腺癌转移和多药耐药相关的关键生物学事件。我们已经确定了乳腺癌EMT的几个标志物成像转移性乳腺癌和转移性乳腺癌的有效治疗,通过抑制癌细胞EMT和再敏感的细胞化疗成像指导下。在本项目中,我们将开发分子MRI和DCE-MRI,以指导使用靶向脂质siRNA纳米颗粒治疗转移性BC来抑制BC EMT。我们将开发靶向多功能脂质siRNA递送系统,以下调促进癌细胞EMT的关键蛋白的表达,从而有效抑制BC EMT并单独治疗转移性BC以及在成像引导下与化疗联合治疗。使用成像技术对新治疗方案的治疗效果进行无创和及时的评估将指导递送系统和治疗方案的优化,以实现最佳可能的结果并治愈疾病。本项目的具体目标是:1)首次建立图像引导的靶向多功能siRNA递送系统无创性抑制EMT治疗转移性乳腺癌的分子成像技术; 2)评估和优化图像引导的EMT调控基因沉默和靶向多功能siRNA递送系统抑制BC EMT和转移; 3)评价和优化多功能siRNA递送系统与化疗药物在治疗TNBC中的图像引导联合治疗。已经获得了大量的初步数据来证明所提出的图像引导治疗方案在治疗转移性乳腺癌中的有效性。我们的长期目标是开发一种图像引导的治疗方法,以有效治疗危及生命的转移性BC。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(1)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ZHENG-RONG LU其他文献

ZHENG-RONG LU的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ZHENG-RONG LU', 18)}}的其他基金

Smart nanoparticles regulating oncogenic IncRNA for breast cancer therapy
智能纳米颗粒调节致癌 IncRNA 用于乳腺癌治疗
  • 批准号:
    10307922
  • 财政年份:
    2021
  • 资助金额:
    $ 47.39万
  • 项目类别:
Smart nanoparticles regulating oncogenic IncRNA for breast cancer therapy
智能纳米颗粒调节致癌 IncRNA 用于乳腺癌治疗
  • 批准号:
    10300425
  • 财政年份:
    2018
  • 资助金额:
    $ 47.39万
  • 项目类别:
Smart nanoparticles regulating oncogenic IncRNA for breast cancer therapy
智能纳米颗粒调节致癌 IncRNA 用于乳腺癌治疗
  • 批准号:
    10524128
  • 财政年份:
    2018
  • 资助金额:
    $ 47.39万
  • 项目类别:
Smart nanoparticles regulating oncogenic IncRNA for breast cancer therapy
智能纳米颗粒调节致癌 IncRNA 用于乳腺癌治疗
  • 批准号:
    10755865
  • 财政年份:
    2018
  • 资助金额:
    $ 47.39万
  • 项目类别:
Smart nanoparticles regulating oncogenic IncRNA for breast cancer therapy
智能纳米颗粒调节致癌 IncRNA 用于乳腺癌治疗
  • 批准号:
    10532735
  • 财政年份:
    2018
  • 资助金额:
    $ 47.39万
  • 项目类别:
Smart nanoparticles regulating oncogenic IncRNA for breast cancer therapy
智能纳米颗粒调节致癌 IncRNA 用于乳腺癌治疗
  • 批准号:
    10054176
  • 财政年份:
    2018
  • 资助金额:
    $ 47.39万
  • 项目类别:
Targeted MRI contrast agents for differential diagnosis of prostate cancer
靶向 MRI 造影剂用于前列腺癌的鉴别诊断
  • 批准号:
    9327104
  • 财政年份:
    2017
  • 资助金额:
    $ 47.39万
  • 项目类别:
Targeted MRI contrast agents for differential diagnosis of prostate cancer
靶向 MRI 造影剂用于前列腺癌的鉴别诊断
  • 批准号:
    9903251
  • 财政年份:
    2017
  • 资助金额:
    $ 47.39万
  • 项目类别:
Biodegradable macromolecular CT contrast agents
可生物降解高分子CT造影剂
  • 批准号:
    8790640
  • 财政年份:
    2014
  • 资助金额:
    $ 47.39万
  • 项目类别:
Biodegradable macromolecular CT contrast agents
可生物降解高分子CT造影剂
  • 批准号:
    8870352
  • 财政年份:
    2014
  • 资助金额:
    $ 47.39万
  • 项目类别:

相似海外基金

Impact of actin binding protein Coronin 1C in the pathogenesis of Parkinson's disease
肌动蛋白结合蛋白 Coronin 1C 在帕金森病发病机制中的影响
  • 批准号:
    10392204
  • 财政年份:
    2022
  • 资助金额:
    $ 47.39万
  • 项目类别:
Impact of actin binding protein Coronin 1C in the pathogenesis of Parkinson's disease
肌动蛋白结合蛋白 Coronin 1C 在帕金森病发病机制中的影响
  • 批准号:
    10577415
  • 财政年份:
    2022
  • 资助金额:
    $ 47.39万
  • 项目类别:
Functional Role of Actin-binding Protein Moesin in Renal Tubules.
肌动蛋白结合蛋白 Moesin 在肾小管中的功能作用。
  • 批准号:
    18K06643
  • 财政年份:
    2018
  • 资助金额:
    $ 47.39万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
An actin-binding protein villin in Marchantia polymorpha
地钱中的肌动蛋白结合蛋白绒毛蛋白
  • 批准号:
    18K06287
  • 财政年份:
    2018
  • 资助金额:
    $ 47.39万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
The Analysis of the role of actin-binding protein in tooth germ formation
肌动蛋白结合蛋白在牙胚形成中的作用分析
  • 批准号:
    17K17311
  • 财政年份:
    2017
  • 资助金额:
    $ 47.39万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Interaction between NMDA receptor subunits and drebrin, an actin binding protein
NMDA 受体亚基与肌动蛋白结合蛋白 drebrin 之间的相互作用
  • 批准号:
    16K18376
  • 财政年份:
    2016
  • 资助金额:
    $ 47.39万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
The F-actin binding protein TRIOBP-1 regulates hERG K+ channels
F-肌动蛋白结合蛋白 TRIOBP-1 调节 hERG K 通道
  • 批准号:
    9051240
  • 财政年份:
    2016
  • 资助金额:
    $ 47.39万
  • 项目类别:
Signal transduction of the actin-binding protein cortactin in bacterial pathogenesis
肌动蛋白结合蛋白 cortactin 在细菌发病机制中的信号转导
  • 批准号:
    289286761
  • 财政年份:
    2016
  • 资助金额:
    $ 47.39万
  • 项目类别:
    Research Grants
The role of PPP1r18, an actin binding protein, in osteoclastic bone resorption
肌动蛋白结合蛋白 PPP1r18 在破骨细胞骨吸收中的作用
  • 批准号:
    16K20423
  • 财政年份:
    2016
  • 资助金额:
    $ 47.39万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Control of matrix remodeling through an actin binding protein
通过肌动蛋白结合蛋白控制基质重塑
  • 批准号:
    354556
  • 财政年份:
    2016
  • 资助金额:
    $ 47.39万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了